Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prednisolone does not reduce withdrawal headache: a randomized, double-blind study.

Magne G Bøe1, Ase Mygland, Rolf Salvesen

  • 1Department of Neurology, Sorlandet Hospital, Kristiansand, Norway. magne.geir.boe@sshf.no

Neurology
|May 4, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Definite neuroborreliosis with atypical antibody-profiles: a case report.

Journal of medical case reports·2026
Same author

Are white matter hyperintensities associated with neuroborreliosis? The answer is twofold.

Neuroradiology·2024
Same author

Clinical and laboratory characteristics during a 1-year follow-up in European Lyme neuroborreliosis: A prospective cohort study.

European journal of neurology·2024
Same author

Serum neurofilament light chain associates with symptom burden in Lyme neuroborreliosis patients: a longitudinal cohort study from Norway.

Journal of neurology·2024
Same author

Assessment of cognitive function, structural brain changes and fatigue 6 months after treatment of neuroborreliosis.

Journal of neurology·2022
Same author

Barriers to and facilitators for making emergency calls - a qualitative interview study of stroke patients and witnesses.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2022

Prednisolone did not reduce headache intensity in patients undergoing medication withdrawal for chronic daily headache. This study found no significant difference between prednisolone and placebo groups during the withdrawal period.

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Medicine

Background:

  • Medication overuse headache (MOH) is a common condition.
  • Abrupt drug withdrawal is the primary treatment for MOH.
  • Effective strategies to manage withdrawal symptoms are needed.

Purpose of the Study:

  • To evaluate the efficacy of oral prednisolone in reducing headache intensity during the initial phase of medication withdrawal in patients with probable MOH.
  • To compare prednisolone's effect against a placebo in managing withdrawal headache.

Main Methods:

  • A randomized, double-blind, placebo-controlled study involving 100 patients (aged 18-70) with probable MOH.
  • Patients received either a tapering dose of oral prednisolone (60 mg to 20 mg over 6 days) or a placebo.

Related Experiment Videos

  • Headache intensity was monitored daily via diaries, with the primary endpoint being mean headache intensity during the first 6 days post-withdrawal.

    • Main Results:

    • No significant difference in mean headache intensity was observed between the prednisolone group (MH 1.48) and the placebo group (MH 1.61) during the first 6 days after withdrawal (p = 0.34).
    • Baseline characteristics, including headache frequency and intensity, were similar between the groups.
    • The study included a diverse patient population with migraine, tension-type headache, or both.

    Conclusions:

    • Oral prednisolone is ineffective in alleviating withdrawal headache in unselected patients with chronic daily headache and medication overuse.
    • Further research may be needed to identify specific patient subgroups who might benefit from prednisolone or alternative treatments.